All In Biotech

Drug Trial Radar · NCT06943521

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Tanabe Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Esophageal Cancer
  • Gastric Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Prostate Cancer
  • Urothelial Carcinoma
  • Neuroendocrine Tumor (NET)
  • Neuroendocrine Carcinoma (NEC)
  • Soft Tissue Sarcoma
  • Nuclear Protein in Testis (NUT) Carcinoma

Interventions

  • MT-4561Drug

    i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Event, Dose limiting toxicities (DLTs)Time frame: a 28-day cycle
  2. Number of Patients with Adverse events (AEs)Time frame: Screening through 30 days after last dose

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • National Cancer Center Hospital East

    City, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-Ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.